COVID-19 Antigens Product Range


Code Product Description
39501 Recombinant SARS-CoV-2 Nucleocapsid Protein lysates expressed in baculovirus expression system using the patented KREX™ functional proteomics technology
39502 Recombinant SARS-CoV-2 Spike Protein lysates expressed in baculovirus expression system using the patented KREX™ functional proteomics technology
39503 COVID-19 microarray containing full-length, correctly folded and functional human SARS-CoV-2 and antigens from other respiratory viruses including influenza, SARS and MERS
39504 High-throughput, high multiplex microtitre plate for COVID-19 diagnostic/surveillance test containing full-length, correctly folded and functional human SARS-CoV-2 and antigens from other respiratory viruses including influenza, SARS and MERS
39505 Multiple recombinant Hemagglutinin protein lysates expressed in baculovirus expression system using the patented KREX™ functional proteomics technology
39506 Recombinant MERS and recombinant SARS protein lysates expressed in baculovirus expression system using the patented KREX™ functional proteomics technology

Key Applications

Use Sengenics’ correctly folded spike or nucleocapsid COVID-19 antigens for production of a high-affinity vaccine

Development of an antigen-based COVID-19 sero-diagnostic test for patient screening or immunosurveillance purposes

Fundamental research: characterisation of full-length, correctly folded and functional SARS-CoV-2 antigens

List of Proteins


Disease Protein Name Protein Seq. Length (aa) GenBank Accession ID Expression System Tech
COVID-19 SARS-CoV-2-Nucleocapsid protein full length 419 MN908947.3 Baculovirus – insect cell KREX – BCCP
COVID-19 SARS-CoV-2-Spike protein full length 1273 YP_009724390.1 Baculovirus – insect cell KREX – BCCP
SARS SARS-CoV-Nucleocapsid protein full length 422 NP_828858.1 Baculovirus – insect cell KREX – BCCP
MERS MERS-CoV-nucleocapsid protein full length 413 AKQ21082.1 Baculovirus – insect cell KREX – BCCP


brochure

Advantages of Sengenics’ COVID-19 Antigens and Tests

Correctly folded antigens lead to better immunogenic response

Since most antibodies are thought to recognise discontinuous epitopes on their target proteins, it’s critical that antigens used in serological assays or presented to B-cells for antibody-based vaccine development are in a natively-folded form. The use of our KREX™ technology for the production of the SARS-CoV-2 antigens will ensure these antigens are correctly folded, preserving all conformational antibody binding sites.

Higher sensitivity and specificity than antibody/RT-PCR-based test

Serological-based tests enable the quantification of IgM and other types of Immunoglobulin. In the case of infectious diseases, IgM is the first antibody produced by the body to fight a new infection. Therefore, our test will overcome the limitations of current rtPCR test. It is also crucial for immunosurveillance purposes, during both the pre- and post-infection periods, particularly for disease management during a pandemic.


DOWNLOADS

Resources to access our technology

FAQs

Your technical questions – answered

SOLUTIONS

One technology – endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

2008 – 2020© Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X